BIOCYTOGEN
21.6.2024 12:51:24 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform.
RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the entire human antibody heavy chain variable region genes and a single light chain variable region gene. This enables the generation of highly diverse fully human antibodies that share a common light chain, effectively avoiding light-heavy chain mismatches during the assembly of bispecific antibodies, thereby significantly reducing the complexity of the CMC process. The molecular structures of these bispecific antibodies resemble monoclonal antibodies, exhibiting favorable physicochemical properties. Leveraging RenLite® and RenLite® KO mice, Biocytogen has generated a library of antibodies targeting over 200 TAA targets, enabling the rapid development of bispecific antibody and bispecific antibody-drug-conjugate (ADC) therapies.
In addition to the RenLite® platform, Biocytogen’s independently developed RenMice® series includes RenMabTM, RenNano®, RenTCRTM and RenTCR-mimicTM platforms. These five fully human antibody/TCR mouse platforms cater to the diverse R&D needs of pharmaceutical companies globally. Since their debut in 2019, the RenMice® platforms have garnered widespread recognition within the biotech and pharmaceutical industries. As of December 31, 2023, Biocytogen has established 47 target-nominated RenMice® licensing projects with over 20 multinational corporations (MNCs) and biopharmaceutical/biotech companies, including Merck KGaA, Janssen, Xencor, BeiGene and Innovent. The RenMice® platform has generated a library of over 400,000 fully human antibodies against thousands of targets and high-quality candidate antibodies, facilitating 103 projects encompassing co-development, out-licensing, and transfer agreements.
The U.S. patent authorization for the RenLite® platform technology demonstrates Biocytogen’s exceptional innovation capabilities and global competitiveness. Biocytogen will continue to pursue global patent strategies and protect key technologies, offering advanced technology platforms and robust intellectual property protection for its partners. Besides the United States, patent applications for the RenLite® platform have been submitted in China, Europe, Japan, South Korea, Canada, Singapore, Russia, Israel, Australia, and other countries and regions with authorizations in progress.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620000304/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Awarded Culcairn Battery Contract by Neoen in Australia30.6.2026 09:06:00 CEST | Press release
The landmark Culcairn Battery contract builds on the successful delivery of Neoen’s Blyth Battery by NHOA Energy in Australia, strengthening the long-standing relationship between both companies NHOA Energy, global provider of utility-scale energy storage systems, has been awarded notice-to-proceed by Neoen, one of the world’s leading renewable energy companies, on the latter’s Culcairn Battery, a 215 MW / 963 MWh project to be installed in New South Wales (NSW), Australia. The project will be delivered under an EPC contract in partnership with a joint venture between Equans Solar & Storage and Bouygues Construction Australia and marks a significant new milestone in the long-standing partnership between Neoen and NHOA Energy in Australia. The announcement follows the successful delivery of work by NHOA Energy on Neoen’s 238.5 MW / 477 MWh Blyth Battery in South Australia, in operation since early 2025, and reaffirms NHOA Energy’s leading role in the growth of large-scale energy storage
Manago AI, Formerly SALESmanago, Unveils New Identity and Agentic AI Capabilities to Help Brands Move Faster and Make Powerful Marketing Feel Simple30.6.2026 09:00:00 CEST | Press release
- Manago AI helps brands understand every customer and turn insights into personalised engagement in minutes, dramatically reducing marketing complexity Manago AI today announces the next evolution of its Customer Engagement Platform, combining a new brand identity, agentic AI capabilities, an improved user experience, and a simplified commercial model designed to help growing companies realise value faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630694104/en/ From left: Marcin Stelmach, Director of Customer Success, Klaudia Penkalla, Chief of Staff, Phil Draper, CEO, and Marek Broda, CDFO The launch coincides with the company’s rebrand from SALESmanago, one of the first marketing automation platforms in Europe, to Manago AI. This reflects a broader business transformation focused on helping marketers move faster, reduce complexity and achieve value sooner through AI-powered customer engagement. Designed for eComm
Ampowr and Indonesia's Ministry of Villages Sign Agreement to Electrify Communities Without Reliable Power30.6.2026 09:00:00 CEST | Press release
A four-village pilot opens a staged path toward as many as 300 villages, transferring Ampowr’s solar, storage, and energy-management technology to support education, healthcare, food production, and rural enterprise. Ampowr has signed a Memorandum of Understanding with Indonesia's Ministry of Villages and Development of Disadvantaged Regions (Kemendes PDT) to bring reliable, clean electricity to villages with little or no power. The agreement was signed in Jakarta by Secretary General Taufik Madjid and Ampowr's Indonesian entity, PT Ampowr IES Indonesia, building on the company's existing sales presence in the city. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630616370/en/ Secretary General (Sekjen) of the Ministry of Villages and Development of Disadvantaged Regions (Kemendes PDT), Taufik Madjid, signed a Memorandum of Understanding with Ampowr Co-CEO, Eric van Honk. Indonesia has 75,266 villages, according to the Min
FPT Achieves SAP® Silver Partner Status in the SAP® PartnerEdge® Program, Expanding SAP Capabilities for European Enterprises30.6.2026 08:00:00 CEST | Press release
FPT announced today that it has achieved SAP silver partner status in the SAP® PartnerEdge® program, recognizing the company's proven customer success, differentiated SAP offerings, and ongoing commitment to SAP certifications. The recognition reflects FPT's growing presence in Europe for SAP technology ecosystems and its experience supporting leading enterprises, including E.ON, RWE, and IONITY, across SAP transformation, application management, and integration initiatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629805729/en/ Through its SAP practice in Europe, FPT provides organizations with comprehensive SAP capabilities designed to support business transformation and maximize the value of their SAP investments, including: End-to-end SAP services spanning consulting, implementation, integration, migration, optimization, application management, and managed services. SAP software licensing and lifecycle support,
Regnology Launches Regnology Risk Hub (RRiH) Ascend to Deliver Governed, AI Powered Intelligence to Balance Sheet and Enterprise Risk Management30.6.2026 08:00:00 CEST | Press release
Powered by RGI, Regnology’s governed intelligence layer, the solution enables proactive, real-time decision-making across treasury, liquidity, and enterprise risk Regnology, a global leading provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the launch of Regnology Risk Hub (RRiH) Ascend, the next evolution of the Regnology Risk Hub (RRiH), now fully integrated into the Ascend platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629063140/en/ Designed to help financial institutions move from reactive risk monitoring to proactive decision-making, RRiH Ascend leverages the combined expertise of the acquired OneSumX for Risk solution from Wolters Kluwer and Moody’s regulatory reporting & ALM solutions, bringing together comprehensive risk coverage, advanced analytics and governed intelligence in a single, cloud-native platform. The solution delivers integrated, enterpris
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom